Clinical Trial Update: A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/ Phase 2 trial evaluating HLX301, a TIGIT×PD-L1 bispecific, in locally advanced/metastatic solid tumors or lymphoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Tumors

Drugs mentioned

• HLX301 (TIGIT×PD-L1 bispecific)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Advanced Tumors, Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN